Form 4: IGMS Merger Completes; Redmile Exits Position

IGM Biosciences, Inc. completed its merger with Concentra Biosciences, LLC, resulting in Redmile Group, LLC disposing of all its equity and warrant holdings.

Summary

• IGM Biosciences, Inc. completed its merger with Concentra Merger Sub V, Inc., a subsidiary of Concentra Biosciences, LLC, on August 14, 2025.
• The tender offer for outstanding shares of Common Stock and Non-Voting Common Stock expired on August 13, 2025.
• Shareholders received $1.247 in cash per share, plus one Contingent Value Right (CVR) per share.
• Pre-funded warrants were cancelled, with holders receiving a cash amount based on the offer price minus the exercise price, plus one CVR per underlying share.
• Redmile Group, LLC and Jeremy Green, as reporting persons, disposed of 2,964,843 shares of Common Stock, 7,199,325 shares of Non-Voting Common Stock, and 667,666 Pre-Funded Warrants.
• Following these transactions, Redmile Group, LLC and Jeremy Green hold 0 shares and warrants in IGM Biosciences, Inc.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting persons as they successfully exited their investment in IGM Biosciences, Inc. through a pre-arranged merger, receiving cash and contingent value rights. While the CVRs introduce some uncertainty, the overall transaction represents a liquidity event and a realization of investment.

Positives

• Successful completion of the tender offer and merger transaction for IGM Biosciences, Inc.
• Shareholders received a cash payment of $1.247 per share, providing immediate liquidity.
• The inclusion of Contingent Value Rights (CVRs) offers potential future upside based on specific terms.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale strategy for the reporting persons.

Negatives

• Redmile Group, LLC and Jeremy Green no longer hold any direct beneficial ownership in IGM Biosciences, Inc. following the merger.
• The value of the CVRs is contingent and not guaranteed, introducing uncertainty regarding potential future payments.
• Loss of equity participation in the future growth and operations of IGM Biosciences, Inc. for former shareholders.

Risks

• The value of the Contingent Value Rights (CVRs) is subject to specific terms and conditions outlined in the CVR Agreement, meaning their ultimate value is uncertain and contingent on future events.
• No further equity upside for former shareholders as the company is now a wholly-owned subsidiary.

Future Outlook

The future outlook for former IGM Biosciences, Inc. shareholders includes potential additional value from Contingent Value Rights (CVRs), which are subject to specific terms and conditions outlined in a CVR Agreement. The company itself is now a wholly-owned subsidiary of Concentra Biosciences, LLC, and its future operations will be under the parent company's direction.

Management Comments

• Michael Lee, a managing director of Redmile, resigned as a member of the board of directors of the Issuer immediately prior to the Merger Closing.

Industry Context

This transaction represents a consolidation event within the biotechnology sector, where smaller companies like IGM Biosciences, Inc. are acquired by larger entities or private equity firms like Concentra Biosciences, LLC. Such mergers are common strategies for larger players to acquire specific assets, pipelines, or technologies, and for investors like Redmile Group to realize returns on their investments.

Comparison to Industry Standards

• NA. This Form 4 reports a specific transaction (merger completion and share disposition) rather than operational or financial performance that would typically be benchmarked against industry standards or comparable companies. The terms of the merger, including the cash price and CVRs, would be evaluated against similar biotech acquisitions, but the filing does not provide sufficient detail for such a comparative assessment.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders (former): Received cash and CVRs, losing direct equity ownership.
• Employees: Not directly addressed, but typically impacted by changes in ownership and management structure post-merger.
• Redmile Group, LLC: Successfully exited its investment, realizing value through the merger.

Next Steps

• Realization of value from Contingent Value Rights (CVRs) based on future events and terms of the CVR Agreement.

Key Dates

Keywords

IGM Biosciences, IGMS, Redmile Group, Merger, Tender Offer, Contingent Value Right, CVR, Form 4, SEC Filing, Biotechnology, Acquisition, Shareholder Exit